Holen Sie sich die Stockscreener-App
0.557
2.35%
-0.0134
Vorhandelsmarkt:
.56
0.003
+0.54%
Galmed Pharmaceuticals Ltd Aktie (GLMD) Neueste Nachrichten
GLMD Forecast — Price Target — Prediction for 2027 - TradingView
GLMD Should I Buy - Intellectia AI
Galmed Pharmaceuticals Ltd. Actuals & Estimates (NASDAQ:GLMD) - TradingView
GPH Forecast — Price Target — Prediction for 2027 - TradingView
Price to book forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to revenue forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Price to sales forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Enterprise value to EBIT forward of Galmed Pharmaceuticals Ltd. – NASDAQ:GLMD - TradingView
Galmed completes acquisition of medical device firm Colospan - Investing.com UK
Galmed Pharmaceuticals finishes restructured Colospan deal - grafa.com
Form 6K Galmed Pharmaceuticals Ltd For: 22 June By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals Ltd. Announces Restructured Acquisition Terms For Colospan Ltd. - TradingView
Galmed Pharmaceuticals Closes Amended All-Cash Colospan Acquisition With Earnout Structure - TipRanks
Galmed completes acquisition of medical device firm Colospan By Investing.com - Investing.com Nigeria
Galmed (NASDAQ: GLMD) closes Colospan acquisition; $3.3M cash, up to $2M earnout - Stock Titan
Galmed (NASDAQ: GLMD) completes Colospan acquisition with cash and earnout - Stock Titan
Galmed buys CG-100 maker Colospan, eyes faster EU sales - Stock Titan
Galmed Pharmaceuticals Ltd (GLMD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Galmed Pharmaceuticals Ltd - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Institutional Confidence - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Valuation: PE, PB & Fair Value Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Galmed Pharmaceuticals Ltd (GLMD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Galmed Pharmaceuticals (GLMD) Slips 7.31% as Stock Tests Key Support at $0.54New Highs New Lows - newsline.com
GLMD Q4 2025 Earnings: EPS Misses Estimates Amid Pre-Revenue PhaseEarnings Recovery Stocks - newsline.com
Maxim Group Maintains Galmed Pharmaceuticals(GLMD.US) With Hold Rating, Announces Target Price $0.55 - Moomoo
GLMD Q4 2025 Earnings: EPS Misses Estimates by Significant MarginEBITDA Analysis - newsline.com
Galmed acquires Colospan in $4.5M deal as it eyes $6B GI dx market - Fierce Biotech
Galmed to acquire Colospan for USD 4.5M - Medical Buyer
Galmed to acquire medical device firm Colospan for $4.5M By Investing.com - Investing.com Australia
Galmed to Acquire Colospan in Deal Expanding GI Medtech Platform - citybiz
Galmed Pharmaceuticals to Acquire Colospan, targeting $6B GI market - grafa.com
Incyte, Galmed, and Johnson & Johnson Announce Acquisitions Totaling $3 Billion - geneonline.com
Galmed to acquire medical device firm Colospan for $4.5M - Investing.com UK
Galmed Pharmaceuticals to Acquire Colospan and Commit $6 Million to European Expansion - TipRanks
Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - The AI Journal
Galmed Pharmaceuticals (NASDAQ: GLMD) files amendment adding auditor consent - Stock Titan
Galmed (NASDAQ: GLMD) registers 7.5M shares; agrees to buy Colospan - Stock Titan
[6-K] Galmed Pharmaceuticals Ltd. Current Report (Foreign Issuer) | GLMD SEC FilingForm 6-K - Stock Titan
Press Release: Galmed Pharmaceuticals to Acquire Colospan to Create a GI-Focused Platform Targeting a $6 Billion Market - Moomoo
GLMD News | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
Galmed and Tissue Dynamics Reveal New Metabolic Target for Cardiac Fibrosis With Aramchol Combo - TipRanks
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data By Investing.com - Investing.com South Africa
Galmed (GLMD) and Tissue Dynamics show fourfold fibrosis cut in human heart organoids - Stock Titan
Galmed, Tissue Dynamics report preclinical cardiac fibrosis data - Investing.com
Tissue Dynamics and Galmed Unveil Unknown Metabolic Pathway for Cardiac Fibrosis and Heart Failure which Supports the Development of Aramchol for Cardiac Fibrosis - PR Newswire
Galmed Pharmaceuticals (GLMD) Surges 9.35% as Shares Test Key ResistanceOutside Reversal - The Legal Advocate
Galmed Pharmaceuticals (GLMD) Surges 9.5%: Testing Key Resistance at $0.71Momentum Trade - The Legal Advocate
GLMDGalmed Pharmaceuticals Ltd Stock Price and Quote - Finviz
GLMD Stock Price, Quote & Chart | GALMED PHARMACEUTICALS LTD (NASDAQ:GLMD) - ChartMill
GLMD Q1'26 Earnings: EPS estimate is (0.38) USD - TradingView
Galmed Pharmaceuticals Ltd expected to post a loss of 38 cents a shareEarnings Preview - TradingView
Number of shareholders of Galmed Pharmaceuticals Ltd. – FWB:GPH - TradingView
0.05%
0.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):